{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-039652","form_type":"8-K","ticker":"BFRI","cik":"0001858685","company_name":"Biofrontera Inc.","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.106536+00:00","generated_at":"2026-05-30T19:36:20.089647+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA approves Biofrontera's sNDA for up to 3 tubes of Ameluz per treatment","bullets":["FDA increased max dosage from 1 to 3 tubes of Ameluz per PDT treatment for actinic keratosis.","Approval supported by two Phase 1 safety studies (116 patients) showing equivalent safety profile.","CEO notes work with Medicare and commercial payers to obtain reimbursement for label update.","AK affects ~58M people in US; ~13M treatments annually; up to 60% of SCCs start as untreated AK."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-039652","json":"https://secwatch.observer/filing/0001493152-24-039652.json","markdown":"https://secwatch.observer/filing/0001493152-24-039652.md","text":"https://secwatch.observer/filing/0001493152-24-039652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224039652/0001493152-24-039652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858685/000149315224039652/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:36:20.089647+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}